Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;9(2):837-839.
doi: 10.21037/tau.2020.03.24.

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer

Ching-Yu Lin  1   2 , Chih-Pin Chuu  1   3
Affiliations
Editorial

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer

Ching-Yu Lin et al. Transl Androl Urol. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.03.24). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Progression of treatment-refractory castration-resistant PCa. The proposed mechanism and progression sequence suggested by Labrecque et al. in (9). The PCa cells after receiving ADT can progress to either ARPC, AMPC, SCNPC, or DNPC. ARPC can progress to ARLPC, DNPC, or QUAPC. ADT, androgen deprivation therapy; ABI, abiraterone; ENZ, enzalutamide; PC, hormone-sensitive prostate cancer; ARPC, AR-high prostate cancer; AMPC, amphicrine prostate cancer; SCNPC, small cell or NE prostate cancer; DNPC, double-negative prostate cancer; ARLPC, AR-low prostate cancer; SQUAPC, squamous prostate cancer.
See this image and copyright information in PMC

Comment on

References

    1. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-79. 10.3322/canjclin.52.3.154 - DOI - PubMed
    1. Chuu CP, Kokontis JM, Hiipakka RA, et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011;18:63. 10.1186/1423-0127-18-63 - DOI - PMC - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. 10.1056/NEJMoa040720 - DOI - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. 10.1056/NEJMoa041318 - DOI - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. 10.1056/NEJMoa1014618 - DOI - PMC - PubMed